Superluminal has raised $60 million in a Series B round to drive its first clinical study, according to finance reporting. The funding is positioned to support the transition from preclinical development into a clinical program. For early-stage biotech, a Series B of this scale typically indicates investor confidence in lead assets and a clear path through IND-enabling work, clinical site readiness, and trial design. It also suggests the company expects to move quickly once safety and manufacturing requirements are met. The round will likely increase competitive pressure in its therapeutic area and accelerate timelines for partner discussions and follow-on financing.